The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a Therapy Driven Route to High-Grade Transformation
Tumour evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumours (PanNETs) in particular, show frequent progression from a low/intermediate to a high-grade disease. To understand the molecular mechanisms underlying this phenomenon, we performed multi-omics analysis of 32 longitudinal samples from six metastatic PanNET patients. Following MEN1 inactivation, PanNETs exhibit genetic heterogeneity on both spatial and temporal dimensions with parallel and convergent tumuor evolution involving the ATRX/DAXX and mTOR pathways. Following alkylating chemotherapy treatment, some PanNETs develop mismatch repair deficiency and acquire a hypermutator phenotype. This DNA hypermutation phenotype was only found in cases that also showed transformation into a high-grade PanNET. Overall, our findings contribute to broaden the understanding of metastatic PanNET, and suggests that therapy driven disease evolution is an important hallmark of this disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2024) vom: 10. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Backman, Samuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 05.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2024.01.08.24300723 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368024822 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368024822 | ||
| 003 | DE-627 | ||
| 005 | 20240205232230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240205s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.01.08.24300723 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM368024822 | ||
| 035 | |a (NLM)38313278 | ||
| 035 | |a (PII)2024.01.08.24300723 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Backman, Samuel |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a Therapy Driven Route to High-Grade Transformation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Tumour evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumours (PanNETs) in particular, show frequent progression from a low/intermediate to a high-grade disease. To understand the molecular mechanisms underlying this phenomenon, we performed multi-omics analysis of 32 longitudinal samples from six metastatic PanNET patients. Following MEN1 inactivation, PanNETs exhibit genetic heterogeneity on both spatial and temporal dimensions with parallel and convergent tumuor evolution involving the ATRX/DAXX and mTOR pathways. Following alkylating chemotherapy treatment, some PanNETs develop mismatch repair deficiency and acquire a hypermutator phenotype. This DNA hypermutation phenotype was only found in cases that also showed transformation into a high-grade PanNET. Overall, our findings contribute to broaden the understanding of metastatic PanNET, and suggests that therapy driven disease evolution is an important hallmark of this disease | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Botling, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Nord, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosal, Suman |e verfasserin |4 aut | |
| 700 | 1 | |a Stålberg, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Juhlin, C Christofer |e verfasserin |4 aut | |
| 700 | 1 | |a Almlöf, Jonas |e verfasserin |4 aut | |
| 700 | 1 | |a Sundin, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Moens, Lotte |e verfasserin |4 aut | |
| 700 | 1 | |a Eriksson, Barbro |e verfasserin |4 aut | |
| 700 | 1 | |a Welin, Staffan |e verfasserin |4 aut | |
| 700 | 1 | |a Hellman, Per |e verfasserin |4 aut | |
| 700 | 1 | |a Skogseid, Britt |e verfasserin |4 aut | |
| 700 | 1 | |a Pacak, Karel |e verfasserin |4 aut | |
| 700 | 1 | |a Mollazadegan, Kazhan |e verfasserin |4 aut | |
| 700 | 1 | |a Åkerström, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Crona, Joakim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2024) vom: 10. Jan. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.01.08.24300723 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 01 | ||